TheraRadar

Pharma Intelligence, Simplified

Company Portfolios →

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

31 active trials across 6 therapeutic areas

31
Active Trials
22
Phase 1
22
Phase 2
4
Phase 3
6
Therapeutic Areas
Portfolio Concentration: 77% of active trials in Oncology

Oncology

24 active / 45 total
Solid Tumor (Advanced)
10 active
12 total since 2015
SCLC
5 active
5 total since 2015
Hepatocellular Carcinoma
2 active
3 total since 2015
Cervical Cancer
2 active
2 total since 2015
Myelofibrosis
1 active
7 total since 2015
NSCLC
1 active
4 total since 2015
Lung Cancer (General)
1 active 1 Ph3
1 total since 2015
Non-Hodgkin Lymphoma
1 active
1 total since 2015
Prostate Cancer
1 active
1 total since 2015
Thyroid Cancer
0 active
4 total since 2015
Esophageal Cancer
0 active
1 total since 2015
Gastric Cancer
0 active
1 total since 2015
MDS
0 active
1 total since 2015
AML
0 active
1 total since 2015
Colorectal Cancer
0 active
1 total since 2015

Immunology

5 active / 11 total
Atopic Dermatitis
2 active 2 Ph3
4 total since 2015
Rheumatoid Arthritis
2 active
2 total since 2015
Ankylosing Spondylitis
1 active 1 Ph3
4 total since 2015
Psoriasis
0 active
1 total since 2015

Dermatology

1 active / 4 total
Alopecia
1 active
4 total since 2015

Cardiovascular

1 active / 1 total
Atrial Fibrillation
1 active
1 total since 2015

Respiratory

0 active / 2 total
Idiopathic Pulmonary Fibrosis
0 active
1 total since 2015
Pneumonia
0 active
1 total since 2015

Infectious Disease

0 active / 1 total
COVID-19
0 active
1 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)